2cureX
2cureX AB is a Swedish listed commercial company focused on patient access and market development for precision oncology solutions. Its business is centered on the IndiTreat® platform, which is used in colorectal cancer care and is supported through a group structure that separates commercialization from product development and regulatory work.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueFunctional precision medicine testing used in colorectal cancer care.
Commercial and workflow support that helps patients reach testing pathways.
Coordination around hospital installation and clinical workflow integration.
Support for external partners, including training and commercial materials.
Customers
2cureX serves newly diagnosed colorectal cancer patients through a direct-to-patient access model, while also working with hospitals and treating physicians who control clinical entry points. It also engages commercial partners and, potentially, pharmaceutical collaborators for future precision-oncology applications. The buying decision is driven by clinical appropriateness, workflow fit, and the ability to access the IndiTreat® platform through the relevant care pathway.
Patients are the end users of the direct-to-patient model and seek access to IndiTreat where clinically appropriate.
Hospitals buy into installation and workflow integration because they are the clinical setting for IndiTreat deployment.
Physicians do not buy the product directly, but they are critical gatekeepers for eligibility and referral.
Partners support market access, patient coordination, and local commercial execution.
Potential future partners may use data-driven insights and treatment guidance in precision oncology programs.
Strategy
2cureX’s strategy is to build a direct-to-patient commercial model that complements hospital-based oncology care and improves access to IndiTreat®. The company also relies on a split-group structure in which commercialization sits with 2cureX AB while development, regulatory approval, and hospital installation sit with 2cureX A/S. Strategic partnerships are used to extend reach into patient access, hospital workflows, and future precision-oncology collaborations.
Creates a clearer route to patients and reduces dependence on the old distributor-led model.
Hospital installations are needed for broader clinical adoption and recurring access.
External partners can extend commercial reach and create future data or pharma use cases.
Geography
2cureX is headquartered in Sweden and listed on Nasdaq First North Growth Market, while its operating history and group structure also connect it to Denmark and Germany. The company has historically built commercial reach across Europe, with reported distribution presence in multiple European countries and a focus on European oncology markets. Geography matters because hospital access, reimbursement, and clinical adoption differ significantly by country, shaping how quickly IndiTreat® can be deployed.
Risks
2cureX operates in an emerging precision-oncology market where commercialization, reimbursement, and clinical adoption remain uncertain. The business is also exposed to partnership dependency, regulatory change, and execution risk because its model depends on successful hospital deployment and coordinated access pathways. As a small listed company with limited revenues, financing discipline and key-person continuity are also important risks.
- Commercialization riskImpact: HighLikelihood: High
Revenue depends on converting clinical interest into actual patient access and hospital use.
Exposure: IndiTreat® access model
- Partnership dependencyImpact: HighLikelihood: High
The model relies on 2cureX A/S, hospital partners, and potential collaborators to execute the pathway.
Exposure: Strategic agreements and LOIs
- Financing and liquidity riskImpact: HighLikelihood: High
The company has limited revenues and must fund commercialization and operating needs.
Exposure: Small-cap listed entity
- Regulatory and market-access riskImpact: MediumLikelihood: High
Hospital installation and patient access depend on local regulatory and reimbursement conditions.
Exposure: Europe
- Key personnel riskImpact: MediumLikelihood: Medium
Execution depends on a small team with specialized commercial and oncology expertise.
Exposure: Management and operating team
Accounting
Judgemental itemsNet sales have been minimal, so any future patient-access or partner revenue will be important and timing-sensitive.
Impact: Could materially change reported growth and comparability.
Board fees and other accrued costs are a meaningful part of the cost base in a small company.
Impact: Affects short-term liabilities and operating expense timing.
The split between AB and A/S creates related-party and intra-group accounting considerations.
Impact: Can affect profit, receivables, and equity presentation.
Historical subsidiary impairments and sale gains show that carrying values can be judgmental.
Impact: Can create volatility in non-operating results.
Similar listed companies
Publicly listed companies with a comparable business focus.
Isofol Medical
ISOFOL · Health Care
Isofol Medical AB is a Swedish biotechnology company focused on the development of arfolitixorin, a drug candidate aimed at improving treatment outcomes for metastatic colorectal cancer.
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
Medivir
MVIR · Health Care
Medivir AB is a Swedish pharmaceutical company focused on the development of innovative treatments for serious diseases.
LadRx Corp
Biological Products, (No Diagnostic Substances)
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development.
Carasent
CARA · Health Care
Carasent is a Swedish company specializing in digital services for the healthcare industry.
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Last updated: 24/09/2026